苯酚神经溶解术治疗痉挛的实践模式
该回顾性研究分析了185例痉挛患者接受的293次苯酚神经溶解术,其中卒中占41.0%、创伤性脑损伤占28.6%、脊髓损伤占24.3%。77.5%的患者同时接受药物治疗,每次手术平均使用10.95 ml苯酚,54.9%的诊疗记录了术后评估且其中84.5%报告主观获益。
要点
- 苯酚神经溶解术用于多种功能目标,包括预防挛缩和改善步态。
- 最常注射的神经为闭孔神经(35.8%)及坐骨神经至腘绳肌和内收大肌分支(27.0%)。
- 术后不良事件包括疼痛(4.0%)、肿胀和炎症(2.7%)、感觉异常(0.7%)和低血压(0.7%)。
核心结论
- 苯酚神经溶解术目前用于减少痉挛以实现多种功能目标,包括预防挛缩和改善步态。
- 根据痉挛模式,上肢和下肢的众多周围神经可作为苯酚神经溶解术的治疗靶点。
研究设计与样本
- 回顾性综述,纳入185例痉挛患者共293次苯酚神经溶解术,地点为一家学术康复医院和诊所。
- 收集患者人口学特征、伴随痉挛治疗及手术相关信息。
主要发现
- 队列中男性占71.9%,住院手术占61.6%。
- 神经系统诊断包括卒中(41.0%)、创伤性脑损伤(28.6%)和脊髓损伤(24.3%)。
- 骨骼肌诊断包括痉挛性偏瘫或轻瘫(51.3%)、四肢瘫(38.4%)和截瘫(9.2%)。
- 77.5%的患者在苯酚神经溶解术时接受伴随药物治疗。
- 注射引导方式包括电刺激和超声(69.3%)或仅超声(27.3%)。
关键数值与推荐
- 每根神经平均注射苯酚3.48 ml,每次手术平均使用苯酚10.95 ml。
- 最常注射的神经为闭孔神经(35.8%)及坐骨神经至腘绳肌和内收大肌分支(27.0%)。
- 54.9%的诊疗记录了苯酚神经溶解术后评估,其中84.5%报告主观获益。
- 术后不良事件包括疼痛(4.0%)、肿胀和炎症(2.7%)、感觉异常(0.7%)和低血压(0.7%)。
临床怎么用
- 苯酚神经溶解术可针对上肢和下肢的周围神经,依据痉挛模式选择靶点。
- 多数患者同时接受药物治疗,注射引导多采用电刺激和超声或仅超声。
- 术后应记录评估,关注主观获益及疼痛、肿胀、感觉异常和低血压等不良事件。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present practice patterns for phenol neurolysis procedures conducted for spasticity management. DESIGN: A retrospective review of 185 persons with spasticity who underwent phenol neurolysis procedures (n = 293) at an academic rehabilitation hospital and clinic. Patient demographics, concomitant spasticity treatments, and procedure relevant information were collected. RESULTS: The cohort included 71.9% males and 61.6% inpatient procedures. Neurological diagnoses included stroke (41.0%), traumatic brain injury (28.6%) and spinal cord injury (24.3%). Musculoskeletal diagnoses included spastic hemiplegia or paresis (51.3%), tetraplegia (38.4) and paraplegia (9.2%). At the time of phenol neurolysis, most patients (77.5%) received concomitant pharmacological treatments for spasticity. Injection guidance modalities included electrical stimulation and ultrasound (69.3%) or ultrasound only (27.3%). A mean of 3.48 ml of phenol were injected per nerve and 10.95 ml of phenol were used per procedure. Most commonly injected nerves included the obturator nerve (35.8%) and sciatic branches to the hamstrings and adductor magnus (27.0%). Post-phenol neurolysis assessment was recorded in 54.9% of encounters, in which 84.5% reported subjective benefit. Post-procedure adverse events included pain (4.0%), swelling and inflammation (2.7%), dysaesthesia (0.7%) and hypotension (0.7%). CONCLUSION: Phenol neurolysis is currently used to reduce spasticity for various functional goals, including preventing contractures and improving gait. Depending on the pattern of spasticity displayed, numerous peripheral nerves in the upper and lower extremities can be targeted for treatment with phenol neurolysis. Further research into its role in spasticity management, including studies exploring its cost-effectiveness and pharmacological and side-effects compared with other treatment options are needed.
引用
- Karri J, Mas MF, Francisco GE, et al. Practice patterns for spasticity management with phenol neurolysis. J Rehabil Med. 2017. PMID: 28537343. doi:10.2340/16501977-2239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。